Cargando…
KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy
INTRODUCTION AND DESIGN: The introduction of the epidermal growth factor receptor inhibitors (EGFR-I) has increased the treatment options available for patients with metastatic colorectal cancer (mCRC). Two EGFR-I agents currently approved for the treatment of mCRC are the fully human monoclonal ant...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer-Verlag
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840670/ https://www.ncbi.nlm.nih.gov/pubmed/19936839 http://dx.doi.org/10.1245/s10434-009-0811-z |